Loading stock data…
$6.65-0.02 (-0.37%)
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States.
The Oncology Institute, Inc. in the Healthcare sector is trading at $6.65 with a market capitalization of $644M. Wall Street consensus targets $9.40 (5 analysts), implying a +41.4% move over the next 12 months. The stock is currently near its 52-week high of $7.13, remaining 46.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $161.28M↑ | $147.44M↑ | $141.96M↑ | $136.56M↑ | $119.80M |
| Gross Profit | $27.16M↑ | $23.32M↑ | $22.77M↑ | $18.92M↑ | $17.50M |
| Operating Income | -$4.62M↑ | -$6.51M↑ | -$6.91M↑ | -$8.05M↑ | -$11.21M |
| Net Income | -$9.79M↓ | -$2.49M↑ | -$7.51M↑ | -$16.50M↑ | -$17.01M |
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-ho...